PMID- 36224009
OWN - NLM
STAT- MEDLINE
DCOM- 20221014
LR  - 20221028
IS  - 2768-6698 (Electronic)
IS  - 2768-6698 (Linking)
VI  - 27
IP  - 9
DP  - 2022 Sep 28
TI  - HLA-DQA1 and DQB1 Alleles are Associated with Acitretin Response in Patients with 
      Psoriasis.
PG  - 266
LID - 10.31083/j.fbl2709266 [doi]
AB  - BACKGROUND: Psoriasis vulgaris is an immune-mediated inflammatory skin disease. 
      Although the pathogenesis of psoriasis is unclear, genetic susceptibility, such 
      as HLA-C*06:02, is believed to be a major risk factor. However, there is a 
      paucity of knowledge regarding the relationship between genetics and the response 
      to systemic treatment of psoriasis. We hypothesized that genetic variations in 
      human leukocyte antigen (HLA) genes may act as predictors of acitretin treatment 
      in psoriasis. The aim of our study was to explore the presence of HLA gene 
      variants in patients with moderate-to-severe psoriasis receiving acitretin 
      treatment. METHODS: A total of 100 Han Chinese patients with psoriasis completed 
      the study. 24 patients including 16 responders and 8 non-responders underwent 
      deep sequencing by MHC targeted region capture and 76 samples were genotyped by 
      Sanger sequencing (SBT) based HLA typing for validation. RESULTS: Regressions 
      with adjustment for age, sex, body mass index (BMI), and baseline psoriasis area 
      and severity index (PASI) revealed that two HLA alleles (HLA-DQA1*:02:01, 
      DQB*:02:02) were associated with the response to acitretin. The 
      DQA1*0201-positive patients showed a better response to acitretin compared to the 
      DQA1*0201-negative patients (relative risk (RR) = 10.34, 95% confidence interval 
      (CI): 2.62-40.77, p = 0.001), and the DQB1*0202-positive patients manifested a 
      better response to acitretin when compared to the DQB1*0202-negative patients (RR 
      = 21.01, 95% CI: 2.53-174.27, p = 0.005). CONCLUSIONS: Our observations support 
      the potential role of HLA-DQA1*:02:01 and DQB*:02:02 as pharmacogenetic markers 
      of the acitretin response in patients with psoriasis.
CI  - (c) 2022 The Author(s). Published by IMR Press.
FAU - Zhou, Xingchen
AU  - Zhou X
AD  - Department of Dermatology, Xiangya Hospital, Central South University, 410008 
      Changsha, Hunan, China.
AD  - Department of Pharmacy, Xiangya Hospital, Central South University, 410008 
      Changsha, Hunan, China.
FAU - He, Yijing
AU  - He Y
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      410008 Changsha, Hunan, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, 410008 Changsha, Hunan, China.
FAU - Kuang, Yehong
AU  - Kuang Y
AD  - Department of Dermatology, Xiangya Hospital, Central South University, 410008 
      Changsha, Hunan, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, 410008 Changsha, Hunan, China.
FAU - Chen, Wangqing
AU  - Chen W
AD  - Department of Dermatology, Xiangya Hospital, Central South University, 410008 
      Changsha, Hunan, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, 410008 Changsha, Hunan, China.
FAU - Zhu, Wu
AU  - Zhu W
AD  - Department of Dermatology, Xiangya Hospital, Central South University, 410008 
      Changsha, Hunan, China.
AD  - National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 
      Central South University, 410008 Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Front Biosci (Landmark Ed)
JT  - Frontiers in bioscience (Landmark edition)
JID - 101612996
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-DQ alpha-Chains)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQA1 antigen)
RN  - 0 (HLA-DQB1 antigen)
RN  - LCH760E9T7 (Acitretin)
SB  - IM
MH  - *Acitretin/therapeutic use
MH  - Alleles
MH  - Genetic Predisposition to Disease
MH  - HLA-C Antigens/genetics
MH  - HLA-DQ alpha-Chains
MH  - HLA-DQ beta-Chains/*genetics
MH  - Humans
MH  - *Psoriasis/drug therapy/genetics
OTO - NOTNLM
OT  - acitretin
OT  - human leukocyte antigen
OT  - pharmacogenetics
OT  - psoriasis
OT  - response
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/13 06:00
MHDA- 2022/10/15 06:00
CRDT- 2022/10/12 21:30
PHST- 2022/05/13 00:00 [received]
PHST- 2022/06/23 00:00 [revised]
PHST- 2022/08/02 00:00 [accepted]
PHST- 2022/10/12 21:30 [entrez]
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2022/10/15 06:00 [medline]
AID - S2768-6701(22)00616-5 [pii]
AID - 10.31083/j.fbl2709266 [doi]
PST - ppublish
SO  - Front Biosci (Landmark Ed). 2022 Sep 28;27(9):266. doi: 10.31083/j.fbl2709266.